TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02Termination of a Material Definitive Agreement.
Item 5.02Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On December 1, 2016, Tonix Pharmaceuticals Holding Corp. (the
Company) elected to eliminate the position of Chief Scientific
Officer. In connection with the elimination of such position, the
employment agreement entered into by and between the Company and
Dr. Bruce Daugherty, Ph.D. is being terminated, effective as of
December 31, 2016. Effective as of the date of such termination,
Dr. Daugherty will resign from his positions as the Companys
Chief Scientific Officer, Controller and Secretary and all
positions of the Companys subsidiaries.
to Dr. Daughertys Employment Agreement with the Company, dated
March14, 2014, and previously filed with the Securities and
Exchange Commission as Exhibit 10.01 to the Companys Current
Report on Form 8-K filed on March 19, 2014, Dr. Daugherty will
receive (i)a severance payment equal to his current annual base
salary, (ii) payment of the full cost of health benefits coverage
for Dr. Daugherty and his eligible dependents for one year and
(iii)the automatic acceleration of the vesting and exercisability
of outstanding unvested stock awards as to the number of stock
awards that would have vested over the 12-month period following
the effective date of Dr. Daughertys termination. to his
employment agreement, all payments and benefits to Dr. Daugherty
thereunder are subject to his compliance with the confidentiality
and non-competition provisions thereof and his execution of a
general release of claims against the Company.
Item 8.01Other Events.
On December 7, 2016, the Company will present a poster entitled
The AtEase Study: A Multicenter Randomized Clinical Trial of
the Safety and Efficacy of TNX-102 SL in the Treatment of
Military-Related PTSD (the Poster), at the 55th
Annual Meeting of the American College of Neuropsychopharmacology
being held in Hollywood, Florida. The Poster will be presented by
Dr. Gregory Sullivan, M.D., Chief Medical Officer of the Company.
The foregoing description of the Poster is qualified in its
entirety by reference to the Poster, a copy of which is filed as
Exhibit99.01 to, and is incorporated by reference in, this
report.
The information in this Current Report is being furnished and
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
| 99.01 |
The AtEase Study: A Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSD Poster* |
______
* Furnished herewith.
About TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP)
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session up +0.001 at 0.366 with 655,406 shares trading hands.
